Jacobs Aaron T, Martinez Castaneda-Cruz Diana, Rose Mark M, Connelly Linda
California University of Science and Medicine, 1501 Violet Street, Colton, CA 92324, United States.
California University of Science and Medicine, 1501 Violet Street, Colton, CA 92324, United States.
Biochem Pharmacol. 2022 Oct;204:115209. doi: 10.1016/j.bcp.2022.115209. Epub 2022 Aug 14.
The last 25 years have seen significant growth in new therapeutic options for breast cancer, termed targeted therapies based on their ability to block specific pathways known to drive breast tumor growth and survival. Introduction of these drugs has been made possible through advances in the understanding of breast cancer biology. While the promise of targeted therapy for breast cancer has been clear for some time, the experience of the clinical use of multiple drugs and drug classes allows us to now present a summary and perspective as to the success and impact of this endeavor. Here we will review breast cancer targeted therapeutics in clinical use. We will provide the rationale for their indications and summarize clinical data in patients with different breast cancer subtypes, their impact on breast cancer progression and survival and their major adverse effects. The focus of this review will be on the development that has occurred within classes of targeted therapies and subsequent impact on breast cancer patient outcomes. We will conclude with a perspective on the role of targeted therapy in breast cancer treatment and highlight future areas of development.
在过去25年里，乳腺癌的新治疗选择有了显著增长，这些治疗方法因其能够阻断已知驱动乳腺肿瘤生长和存活的特定途径而被称为靶向治疗。对乳腺癌生物学认识的进步使得这些药物的引入成为可能。虽然乳腺癌靶向治疗的前景在一段时间内已经很明确，但多种药物和药物类别的临床使用经验使我们现在能够对这一努力的成功和影响进行总结并给出观点。在此，我们将回顾临床使用的乳腺癌靶向治疗药物。我们将阐述其适应证的依据，总结不同乳腺癌亚型患者的临床数据、它们对乳腺癌进展和生存的影响以及主要不良反应。本综述的重点将是靶向治疗类别内的发展情况以及对乳腺癌患者预后的后续影响。我们将以对靶向治疗在乳腺癌治疗中的作用的观点作为总结，并突出未来的发展领域。
